"Potential Link Between R.S.V. Vaccines and Rare Neurological Condition"
Federal health officials presented data suggesting a potential link between R.S.V. vaccines and Guillain-Barré syndrome, a rare neurological condition, but emphasized that the connection is still uncertain. The reported cases were small, with an estimated two cases per 100,000 vaccinated people or fewer, and further data is needed to determine the risk. The vaccines in question, Abrysvo by Pfizer and Arexvy by GSK, were approved by the FDA in 2023, and the CDC recommended them for adults aged 60 or older. Ongoing surveillance will provide more clarity on the potential increased risk of Guillain-Barré syndrome after R.S.V. vaccination.